Clinical Trial Opportunities for Patients with HIV Infection

The Division of Infectious Diseases at the Indiana University School of Medicine has conducted clinical trials and research to improve the health and well-being of Indiana adults and adolescents with a variety of infections for over 30 years. They have performed studies in the areas of HIV/AIDS, other sexually transmitted infections (herpes, human papillomavirus, syphilis, gonorrhea, chlamydia), and sexual behavioral medicine.

Indiana University Infectious Diseases Research (IUIDR) is a research group for the Division of Infectious Diseases in the Indiana University School of Medicine. Our group also includes physicians from the Division of Adolescent Medicine and the Department of Microbiology and Immunology who study infections.

Here are a few examples of the opportunities available to patients right now:

  1. A Randomized, Placebo-Controlled Pilot Trial Assessing Two Doses of N-Acetylcysteine on Changes in Oxidative Stress and Endothelial Function in HIV-infected Older Adults Receiving Stable Antiretroviral Therapy (CECARE NAC).
  2. A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Reformulated Raltegravir 1200 mg Once Daily Versus Raltegravir 400 mg Twice Daily, Each in Combination With TRUVADA™, in Treatment-Naïve HIV-1 Infected Subjects. Merck-MK-0518-292, Samir Gupta, PI.
  3. A Phase IIIb, randomized, open-label study of the safety and efficacy of dolutegravir/abacavir/lamuvidine once daily compared to atazanavir and ritonavir plus tenofovir/emtricitabine once daily in HIV-1 infected antiretroviral therapy naïve women (Protocol #117172),” GlaxoSmithKline, Kenneth H. Fife, PI.
  4. “A Phase IIIb, randomized, open-label study of the safety, efficacy, and tolerability of switching to a fixed-dose combination of abacavir/dolutegravir/ lamivudine from current antiretroviral regimen compared with continuation of the current antiretroviral regimen in HIV-1 infected adults who are virologically suppressed (Protocol #201147)”, GlaxoSmithKline, Kenneth H. Fife, PI

Contact information for the Research Team:

For more information, please visit their website:


Leave a Reply